Literature DB >> 8647823

Effect of mutations at serines 1280-1283 on the mitogenic and transforming activities of the insulin-like growth factor I receptor.

S Li1, M Resnicoff, R Baserga.   

Abstract

The insulin-like growth factor I receptor (IGF-IR) controls the extent of cell proliferation in a variety of cell types by at least 3 different ways: it is mitogenic, it causes transformation, and it protects cells from apoptosis. Previous reports indicated that certain domains in the C terminus of the IGF-IR transmitted a transforming signal that is additional to and separate from the mitogenic signal. We have now mutated the four serine residues at 1280-1283 of the IGF-IR, and transfected the mutant receptor into R- cells. Cells expressing the mutant receptor are fully responsive to IGF-I mediated mitogenesis, but are not transformed (no colony formation in soft agar). Several downstream signal transducers are not affected by the mutation, again suggesting a separate pathway for transformation. The mutant receptor can act as a dominant negative for growth, but cannot induce apoptosis in cells with endogenous wild-type receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8647823     DOI: 10.1074/jbc.271.21.12254

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation.

Authors:  W Li; Y X Jiang; J Zhang; L Soon; L Flechner; V Kapoor; J H Pierce; L H Wang
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

2.  14-3-3 proteins interact with the insulin-like growth factor receptor but not the insulin receptor.

Authors:  R W Furlanetto; B R Dey; W Lopaczynski; S P Nissley
Journal:  Biochem J       Date:  1997-11-01       Impact factor: 3.857

Review 3.  14-3-3ζ as a prognostic marker and therapeutic target for cancer.

Authors:  Christopher L Neal; Dihua Yu
Journal:  Expert Opin Ther Targets       Date:  2010-12       Impact factor: 6.902

4.  The differential effects of pp120 (Ceacam 1) on the mitogenic action of insulin and insulin-like growth factor 1 are regulated by the nonconserved tyrosine 1316 in the insulin receptor.

Authors:  P Soni; M Lakkis; M N Poy; M A Fernström; S M Najjar
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  Insulin-like growth factor II stimulates cell proliferation through the insulin receptor.

Authors:  A Morrione; B Valentinis; S Q Xu; G Yumet; A Louvi; A Efstratiadis; R Baserga
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

6.  Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts.

Authors:  Y Min; Y Adachi; H Yamamoto; A Imsumran; Y Arimura; T Endo; Y Hinoda; C-T Lee; S Nadaf; D P Carbone; K Imai
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

7.  Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis.

Authors:  F Peruzzi; M Prisco; M Dews; P Salomoni; E Grassilli; G Romano; B Calabretta; R Baserga
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

8.  Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth.

Authors:  Geraldine M Kelly; Deirdre A Buckley; Patrick A Kiely; David R Adams; Rosemary O'Connor
Journal:  J Biol Chem       Date:  2012-06-08       Impact factor: 5.157

Review 9.  Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Authors:  Rongshi Li; Alan Pourpak; Stephan W Morris
Journal:  J Med Chem       Date:  2009-08-27       Impact factor: 7.446

10.  IGF-I activates caspases 3/7, 8 and 9 but does not induce cell death in colorectal cancer cells.

Authors:  Shi Yu Yang; Capucine Bolvin; Kevin M Sales; Barry Fuller; Alexander M Seifalian; Marc C Winslet
Journal:  BMC Cancer       Date:  2009-05-21       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.